Skip to main content
PBLS logo

PBLS · Parabilis Medicines, Inc. · Financials

Track PBLS — free
$28.67 +0.42 (+1.49%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 198.62K Avg daily vol (3M) 944.98K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Chart any reported metric, KPI or segment over time — the full statement history lives here

No structured figures reported for this view yet.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current debt and lease obligations 2026-09-30 USD 2,000,000 10-Q filed 2026-11-12
Current finance lease liabilities 2026-09-30 USD 684,000 10-Q filed 2026-11-12
Current long-term debt and lease obligations 2026-09-30 USD 750,000 10-Q filed 2026-11-12
Current operating lease liabilities 2026-09-30 USD 7,810,000 10-Q filed 2026-11-12
Current portion of long-term debt 2026-09-30 USD 2,000,000 10-Q filed 2026-11-12
Noncurrent finance lease liabilities 2026-09-30 USD 951,000 10-Q filed 2026-11-12
Noncurrent operating lease liabilities 2026-09-30 USD 30,381,000 10-Q filed 2026-11-12
Short-term borrowings 2026-09-30 USD 1,250,000 10-Q filed 2026-11-12
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.14×
EV/EBIT
—
Peer median 22.71×
P/E (TTM)
—
Peer median 20.45×
Price/Sales (TTM)
—
Peer median 9.19×
Price/Book
3.52×
Peer median 3.78×

Peer medians compare against the 218 similar-size Biotechnology companies (of 594 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1657677 CUSIP 698955101 13F (30d) 124 filings 124 filers Visit website Investor relations